Serological Biomarkers of Dermatomyositis – Associated Interstitial Lung DiseaseXining Liao1, Yuan Liu2, Yuechi Sun2, Shiju Chen2 and Guixiu Shi2*
- *Corresponding Author:
- Guixiu Shi
Department of Rheumatology and Clinical Immunology
The First Affiliated Hospital
Xiamen University, No. 55, Zhenhai Road
Tel: +86 13600932661
Fax: +86 5922137769
E-mail: [email protected]
Received date: October 27, 2016; Accepted date: December 02, 2016; Published date: December 05, 2016
Citation: Liao X, Liu Y, Sun Y, Chen S, Shi G (2016) Serological Biomarkers of Dermatomyositis – Associated Interstitial Lung Disease. J Pulm Respir Med 6:383.doi: 10.4172/2161-105X.1000383
Copyright: © 2016 Liao X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathies (IIM) which is characterized by chronic inflammation of skin and muscle weakness, and often involving other organs, such as skin, heart, gastrointestinal tract, pulmonary, and joints. Interstitial lung disease (ILD) is the most common internal organ manifestation that affects the prognosis of DM patients. The mortality is very high in DM-ILD patients especially in those with rapid ILD due to the lack of effective treatment. An early diagnosis of ILD in DM patients is critical important. In recent years, many studies focused on detecting serological biomarkers that can be used in prediction and evaluation of DM-ILD. Here we reviewed recent studies about serological biomarkers of DM-ILD. An overview of those biomarkers may help us have a better management of DM-ILD and may give us a better understanding about the pathogenesis of DM-ILD.